340B Drug Pricing Program
Not only are 340B Drug Pricing Program hospitals subject to disproportionately greater oversight by the federal government, they outperform drug companies in terms of program compliance to a substantial degree. These discrepancies underscore the need for increased federal oversight of drug…
340B Advocacy Alliance Bulletin for June 13, 2025
The AHA June 4 filed an amicus brief (https://www.aha.org/amicus-brief/2025-06-04-aha-files-brief-defending-tennessees-340b-contract-pharmacy-law) in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from…
AHA files brief defending Tennessee’s 340B contract pharmacy law.
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate models” before they can be implemented, which the department has not yet done for any of the models pursued by the plaintiff drug companies.
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-…
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models.
340B Advocacy Alliance Bulletin for May 14, 2025.
AHA, others files brief defending South Dakota's 340B contract pharmacy law.
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”